NCT05627271 - The 'Wearing Off' Effect of DMT | Biotech Hunter

Enrollment

39

Participants

Timeline

Start Date

January 10, 2023

Primary Completion Date

April 20, 2023

Study Completion Date

April 20, 2023

Conditions

Multiple Sclerosis

Interventions

OTHER

ocrelizumab

Non-interventional, cross-sectional, qualitative study. There is no treatment allocation. Patients prescribed with Disease-modifying therapy in the commercial setting are eligible to enroll into this study.

OTHER

natalizumab

Non-interventional, cross-sectional, qualitative study. There is no treatment allocation. Patients prescribed with Disease-modifying therapy in the commercial setting are eligible to enroll into this study.

OTHER

ofatumumab

Non-interventional, cross-sectional, qualitative study. There is no treatment allocation. Patients prescribed with Disease-modifying therapy in the commercial setting are eligible to enroll into this study.

Trial Locations (1)

Unknown

Novartis Investigative Site, Basel